Roche: Roche's bispecific antibody, Columvi receives European approval for diffuse large Bcell lymphoma after initial therapy
Roche announced that the European Commission has approved Columvi (glofitamab) in combination with gemcitabine and oxaliplatin (GemOx) for the treatment of adult patients with relapsed or refractory
Read full article »
Roche is a Switzerland-based biotechnology company that discovers, develops, and provides diagnostic and pharmaceutical products and services for the healthcare sector.
Read more